262
Participants
Start Date
February 29, 2016
Primary Completion Date
February 6, 2017
Study Completion Date
February 6, 2017
CHF5259 or Placebo administration
Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.
Clinical Trail Site 348-006, Budapest
Clinical Trial Site 348-003, Budapest
Clinical Trial Site 348-004, Budapest
Clinical Trial Site 348-005, Komárom
Clinical Trail Site 348-008, Miskolc
Clinical Trail Site 348-007, Szombathely
Clinical Trial Site 348-002, Létavértes
Clinical Trial Site 348-001, Deszk
Clinical Trail Site 348-009, Seregélyes
Clinical Trial Site 276-002, Großhansdorf
Clinical Trial Site 203-001, Mělník
Clinical Trial Site 203-003, Kralupy nad Vltavou
Clinical Trial Site 203-007, Mladá Boleslav
Clinical Trial Site 203-002, Karlovy Vary
Clinical Trial Site 203-004, Varnsdorf
Clinical Trial Site 203-006, Teplice
Clinical Trial Site 276-003, Bonn
Clinical Trial Site 276-001, Wiesbaden
Clinical Trial Site 203-005, Moravský Krumlov
Clinical Trial Site 276-005, Stuttgart
Clinical Trial Site 642-004, Cluj-Napoca
Clinical Trial Site 642-003, Brasov
Clinical Trial Site 642-001, Codlea
Clinical Trial Site 276-006, Freiburg im Breisgau
Clinical Trial Site 642-005, Bacau
Clinical Trial Site 642-006, Suceava
Clinical Trial Site 276-004, Cottbus
Clinical Trial Site 642-007, Bucharest
Clinical Trial Site 642-008, Bucharest
Clinical Trial Site 642-002, Miercurea-Ciuc
Chiesi Farmaceutici S.p.A.
INDUSTRY